A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...

New details have emerged about how Alzheimer’s disease affects the brain. Researchers led by the Allen Institute for Brain Science in Seattle and University of Washington Medicine have ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

Alzheimer's disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

Rensselaer Polytechnic Institute (RPI) has been awarded two grants by the National Institute on Aging (NIA) to train graduate ...